Decode Age Raises INR 14.48 Cr in Pre-Series A to Expand Longevity & Gut Microbiome Research

The fresh capital will be deployed to accelerate Decode Age’s research-led longevity platform, including biomarker discovery programmes, multi-omics testing capabilities, and gut microbiome research. 

Decode Age, a longevity science organisation focused on ageing biology, biomarkers, and gut microbiome research, has raised Rs 14.48 crore in a Pre-Series A funding round. The round was led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited.

The fresh capital will be deployed to accelerate Decode Age’s research-led longevity platform, including biomarker discovery programmes, multi-omics testing capabilities, and gut microbiome research. The company is also working on science-backed supplement formulations aligned with key hallmarks of ageing.

Founded to make the biology of ageing measurable and actionable, Decode Age operates across ageing biomarkers, precision diagnostics, and microbiome science. The company has developed an integrated longevity research platform spanning multi-omics testing, biomarker identification, and personalised interventions.

A core component of Decode Age’s platform is its whole-genome gut microbiome analysis system, designed to generate high-resolution insights into microbial diversity and its links to immunity, metabolism, and ageing-related biological pathways. The company states that its laboratory workflows emphasise precision and reproducibility, enabling use across research, clinical, and consumer-facing applications.

According to Decode Age, the new funding will support the expansion of its scientific and analytical infrastructure. This includes deeper work in biomarker discovery, scaling its microbiome and multi-omics research pipeline, and advancing formulation research targeting areas such as cellular energy, metabolic regulation, inflammatory pathways, and cognitive health.

The company is also in the process of strengthening its scientific, clinical, and product teams as it looks to expand its research and development capabilities. Decode Age plans to scale its operations to support larger research programmes and international collaborations in longevity and microbiome science.

Dr Krishna Prasad Chigurupati brings over four decades of experience in the pharmaceutical sector, with a background in large-scale manufacturing and drug development. His investment marks an expansion of interest from established pharmaceutical leadership into India’s emerging longevity science and precision health segment.

As part of its next growth phase, Decode Age is focusing on building research capacity that can operate at global scale, while continuing to develop evidence-backed tools and insights related to healthy ageing and microbiome-driven interventions.

Stay tuned for more such updates on Digital Health News